New US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding NGS
Non-regulated information
Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods
Non-regulated information
Biocartis Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting
Non-regulated information
Biocartis Announces CE-marking of its Fully Automated Idylla™ SARS-CoV-2 Test
Non-regulated information
Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness
Non-regulated information
Biocartis and GeneproDx To Collaborate on Fully Automated ThyroidPrint® test on Idylla™
Non-regulated information
Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances
Inside information
Regulated information
Biocartis Announces Market Release of SeptiCyte® RAPID test on Idylla™
Non-regulated information
CORPORATE STATEMENT: Biocartis Joins COVID-19 Testing Industry Consortium of Nineteen Healthcare Community Organizations
Non-regulated information
Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay